Description: Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers episil oral liquid for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; Sancuso, a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting; and Darvias injection, and antineoplastic agent/organic arsenic product indicated for relapsed or refractory peripheral T-cell lymphoma. It is also involved in the development of SP-04, a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. The company was founded in 2006 and is based in Tokyo, Japan.
Home Page: www.solasia.co.jp
Sumitomo Fudosan Shiba-Koen Tower
Tokyo,
105-0011
Japan
Phone:
81 3 5843 8045
Officers
| Name | Title |
|---|---|
| Mr. Yoshihiro Arai | President, CEO & Representative Director |
| Mr. Toshio Miyashita | CFO, GM of Management Headquarters & Director |
| Yasumitsu Shimada | Accounting Manager |
| Yasuaki Manabe | Head of Marketing Division |
| Fumiko Nagahama | Head of Product Development Division |
| Hikaru Osawa | Head of Production Management Division |
| Wataru Kobayashi | Head of Reliability Assurance Division |
| Kozo Yao | Head of Business Development Division |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.5462 |
| Price-to-Sales TTM: | 0.3783 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 24 |